JP2005508896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508896A5 JP2005508896A5 JP2003524561A JP2003524561A JP2005508896A5 JP 2005508896 A5 JP2005508896 A5 JP 2005508896A5 JP 2003524561 A JP2003524561 A JP 2003524561A JP 2003524561 A JP2003524561 A JP 2003524561A JP 2005508896 A5 JP2005508896 A5 JP 2005508896A5
- Authority
- JP
- Japan
- Prior art keywords
- sti571
- pharmaceutical composition
- composition according
- homoharringtonine
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002411 imatinib Drugs 0.000 claims description 22
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 claims 16
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 claims 16
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 claims 16
- 239000000063 antileukemic agent Substances 0.000 claims 8
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 7
- 239000002777 nucleoside Substances 0.000 claims 7
- 229960000684 cytarabine Drugs 0.000 claims 5
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 210000000066 myeloid cell Anatomy 0.000 claims 4
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 230000002559 cytogenic effect Effects 0.000 claims 3
- 230000002489 hematologic effect Effects 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- 206010033661 Pancytopenia Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 208000024389 cytopenia Diseases 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 231100000226 haematotoxicity Toxicity 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 claims 1
- 229950010147 troxacitabine Drugs 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical compound N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31696701P | 2001-09-05 | 2001-09-05 | |
| US60/316,967 | 2001-09-05 | ||
| PCT/IB2002/003992 WO2003020252A2 (en) | 2001-09-05 | 2002-09-05 | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009021692A Division JP2009102408A (ja) | 2001-09-05 | 2009-02-02 | ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508896A JP2005508896A (ja) | 2005-04-07 |
| JP2005508896A5 true JP2005508896A5 (enExample) | 2009-04-02 |
| JP4794816B2 JP4794816B2 (ja) | 2011-10-19 |
Family
ID=23231501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524561A Expired - Fee Related JP4794816B2 (ja) | 2001-09-05 | 2002-09-05 | ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療 |
| JP2009021692A Pending JP2009102408A (ja) | 2001-09-05 | 2009-02-02 | ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009021692A Pending JP2009102408A (ja) | 2001-09-05 | 2009-02-02 | ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6987103B2 (enExample) |
| EP (2) | EP1443933B1 (enExample) |
| JP (2) | JP4794816B2 (enExample) |
| AT (2) | ATE451106T1 (enExample) |
| AU (1) | AU2002337410A1 (enExample) |
| CA (1) | CA2459822C (enExample) |
| CY (2) | CY1109799T1 (enExample) |
| DE (1) | DE60234708D1 (enExample) |
| DK (2) | DK1443933T3 (enExample) |
| ES (2) | ES2383771T3 (enExample) |
| PT (2) | PT1443933E (enExample) |
| WO (1) | WO2003020252A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| US20040192652A1 (en) * | 2002-12-06 | 2004-09-30 | Giles Francis J. | Pharmaceutical combinations and methods for the treatment of leukemia |
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| US7250416B2 (en) * | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| US20070117776A1 (en) * | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
| BRPI0710496A2 (pt) * | 2006-04-07 | 2011-08-16 | Novartis Ag | combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase |
| EP2049096A4 (en) * | 2006-08-02 | 2012-05-09 | Univ South Florida | METHOD FOR TREATING CHRONIC MYELOGENIC LEUKEMIA CELLS |
| AU2008240044B2 (en) * | 2007-04-13 | 2013-09-12 | Teva Pharamceuticals International Gmbh | Oral cephalotaxine dosage forms |
| EP2229160A1 (en) * | 2007-12-07 | 2010-09-22 | ChemGenex Pharmaceuticals, Inc. | Leukemic stem cell ablation |
| JP5617175B2 (ja) | 2008-04-17 | 2014-11-05 | 富士電機株式会社 | ワイドバンドギャップ半導体装置とその製造方法 |
| CN103619168B (zh) * | 2011-06-29 | 2015-09-23 | 宾州研究基金会 | 用于治疗白血病的组合物、方法和药盒 |
| HUE042327T2 (hu) | 2011-08-30 | 2019-06-28 | Astex Pharmaceuticals Inc | Decitabin-származék készítmények |
| WO2017004538A1 (en) | 2015-07-02 | 2017-01-05 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| BR112020002280A2 (pt) | 2017-08-03 | 2020-07-28 | Otsuka Pharmaceutical Co., Ltd. | composto farmacológico e métodos purificação do mesmo |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148955A1 (en) * | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
-
2002
- 2002-09-05 DE DE60234708T patent/DE60234708D1/de not_active Expired - Lifetime
- 2002-09-05 WO PCT/IB2002/003992 patent/WO2003020252A2/en not_active Ceased
- 2002-09-05 PT PT02772653T patent/PT1443933E/pt unknown
- 2002-09-05 EP EP02772653A patent/EP1443933B1/en not_active Expired - Lifetime
- 2002-09-05 DK DK02772653.8T patent/DK1443933T3/da active
- 2002-09-05 AU AU2002337410A patent/AU2002337410A1/en not_active Abandoned
- 2002-09-05 AT AT02772653T patent/ATE451106T1/de active
- 2002-09-05 AT AT09172828T patent/ATE548041T1/de active
- 2002-09-05 ES ES09172828T patent/ES2383771T3/es not_active Expired - Lifetime
- 2002-09-05 DK DK09172828.7T patent/DK2177223T3/da active
- 2002-09-05 ES ES02772653T patent/ES2334774T3/es not_active Expired - Lifetime
- 2002-09-05 PT PT09172828T patent/PT2177223E/pt unknown
- 2002-09-05 CA CA2459822A patent/CA2459822C/en not_active Expired - Fee Related
- 2002-09-05 JP JP2003524561A patent/JP4794816B2/ja not_active Expired - Fee Related
- 2002-09-05 EP EP20090172828 patent/EP2177223B9/en not_active Expired - Lifetime
-
2003
- 2003-03-27 US US10/397,267 patent/US6987103B2/en active Active
-
2009
- 2009-02-02 JP JP2009021692A patent/JP2009102408A/ja active Pending
-
2010
- 2010-02-10 CY CY20101100126T patent/CY1109799T1/el unknown
-
2012
- 2012-06-06 CY CY20121100501T patent/CY1112817T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2320903B1 (en) | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT | |
| US9161946B2 (en) | Dosing methods for treating disease | |
| RU2012148710A (ru) | Органическое соединение для применения при лечении рака печени | |
| CA2442168A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| ES2383771T3 (es) | Homoharringtonina sola o combinada con otros agentes para su utilización en el tratamiento de la leucemia mielógena crónica resistente o intolerante a los inhibidores de la proteína cinasa diferentes al STI571 | |
| JP2009530295A5 (enExample) | ||
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| Tewes et al. | Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study | |
| Poggi et al. | Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer | |
| EA200600200A1 (ru) | Способ лечения синдрома отвыкания от зависимости | |
| Larive et al. | Carboplatin—etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial | |
| DE602004016376D1 (de) | Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs | |
| ATE536178T1 (de) | Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis | |
| Mannis et al. | Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia | |
| AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| US20210315898A1 (en) | Combination therapy for treating cancer | |
| KR20210039413A (ko) | 암의 치료를 위한 병용 요법 | |
| GB2189703A (en) | Vinpocetine | |
| JP2025541662A (ja) | カピバセルチブ及びベネトクラクスの治療用組み合わせ | |
| HK40040830A (en) | Combination therapy for treating cancer | |
| WO2021224381A1 (en) | Combination therapy for treating cancer | |
| EA046230B1 (ru) | Синергическое действие eyp001 и ifn при лечении инфекции hbv | |
| HK40040825A (zh) | 用於治疗癌症的组合疗法 | |
| CN113727719A (zh) | 血癌的新型治疗方法及新型治疗剂 |